Clinical Trial Update: Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluated using donor stem cells with alemtuzumab to prevent organ rejection in kidney transplant recipients; results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: University of Miami | Conditions: Kidney Transplantation, Kidney Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2012-06-21